



ASX Announcement
14 June 2022

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') is delighted to announce the appointment of Mr Sean Gardiner as a non-executive director of the Company.

Pursuant to clause 7.1 of the Subscription Agreement between Optiscan and Orchid Capital Investments Pte. Ltd. dated 21 September 2020, Orchid Capital Investments Pte. Ltd. nominates Mr Sean Gardiner as its new "Subscriber Nominee" (as defined in the Subscription Agreement) to Optiscan's Board of Directors.

Sean is a Managing Director and Head of Private Investments at the Clermont Group. Prior to joining Clermont, Sean worked at Morgan Stanley, where he spent 20 years in equity research across three locations and in seven different roles. In 2000, he joined the London office covering European Technology and Conglomerate stocks before, in 2005, moving to lead the EEMEA Telecom Services team. In early 2008, Sean transferred to Dubai to setup and manage the MENA Equity Research team. Sean relocated to Singapore in 2010 to oversee and manage the broader Asian research product as well as roll out ASEAN Real Estate coverage. In 2016, he was promoted to Head of ASEAN Research and ASEAN Equity Strategist. Prior to Morgan Stanley, Sean served his Chartered Accountancy articles in South Africa and he has a B.Com (PGDA) from the University of Cape Town.

Mr Gardiner said: "I am delighted to join the Board of Optiscan and to support the commercialization of the company's unique technology. Optiscan's imaging and diagnostic technology is making real-time pathology a reality – with the potential to change cancer screening and treatment as we know it. I look forward to working with the wider team to accomplish Optiscan's mission – building on its strong foundations to become an industry leader in this critical medical field."

In commenting on the appointment of Mr Gardiner, Optiscan's Chairman Mr Robert Cooke said "I am delighted that Mr Gardiner is joining the Optiscan Board. Mr Gardiner's broad and deep experience across equity research and investment, and his wide sector experience including in the technology space, will be invaluable to Optiscan as the Company enters the commercialisation stage of Optiscan's technology".

The Board extends a warm welcome to Mr Gardiner and looks forward to working with him and the Clermont Group as Optiscan continues on its growth trajectory.

- ends -

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Prof Camile Farah
CEO & Managing Director – Optiscan Imaging Ltd
E: cfarah@optiscan.com

Phone (61 3) 9538 3333
Website www.OptiScan.com
16 Miles St, Mulgrave VIC 3170

About Optiscan

Optiscan is a global leader in the development, manufacturing and commercialisation of microscopic imaging and related technologies for preclinical, translational and medical applications. Based in Victoria, Australia, Optiscan was established in 1994, and listed on the ASX in 1997 (ASX: OIL). OptiScan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level allowing instant "digital biopsies" for cancer screening, diagnoses and in surgery.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.OptiScan.com

16 Miles St, Mulgrave VIC 3170